tetano
Editor, Senior Moderator
Pathogens
. 2021 Oct 6;10(10):1289.
doi: 10.3390/pathogens10101289.
Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19
Maria Cappuccilli[SUP] 1 [/SUP], Paolo Ferdinando Bruno[SUP] 2 [/SUP], Alessandra Spazzoli[SUP] 2 [/SUP], Matteo Righini[SUP] 3 [/SUP], Marta Flachi[SUP] 4 [/SUP], Simona Semprini[SUP] 5 [/SUP], Laura Grumiro[SUP] 5 [/SUP], Maria Michela Marino[SUP] 5 [/SUP], Pasqua Schiavone[SUP] 5 [/SUP], Elisabetta Fabbri[SUP] 6 [/SUP], Michela Fantini[SUP] 6 [/SUP], Andrea Buscaroli[SUP] 3 [/SUP], Angelo Rigotti[SUP] 4 [/SUP], Gaetano La Manna[SUP] 1 [/SUP], Vittorio Sambri[SUP] 5 [/SUP], Giovanni Mosconi[SUP] 2 [/SUP]
Affiliations
Abstract
Nephropathic subjects with impaired immune responses show dramatically high infection rates of coronavirus disease 2019 (COVID-19). This work evaluated the ability to acquire and maintain protective antibodies over time in 26 hemodialysis patients and 21 kidney transplant recipients. The subjects were followed-up through quantitative determination of circulating SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month period after clinical and laboratory recovery. A group of 143 healthcare workers with no underlying chronic pathologies or renal diseases recovered from COVID was also evaluated. In both dialysis and transplanted patients, antibody titers reached a zenith around the 3rd month, and then a decline occurred on average between the 270th and 300th day. Immunocompromised patients who lost antibodies around the 6th month were more common than non-renal subjects, although the difference was not significant (38.5% vs. 26.6%). Considering the decay of antibody levels below the positivity threshold (15 AU/mL) as "failure", a progressive loss of immunisation was found in the overall population starting 6 months after recovery. A longer overall antibody persistence was observed in severe forms of COVID-19 (p = 0.0183), but within each group, given the small number of patients, the difference was not significant (dialysis: p = 0.0702; transplant: p = 0.1899). These data suggest that immunocompromised renal patients recovered from COVID-19 have weakened and heterogeneous humoral responses that tend to decay over time. Despite interindividual variability, an association emerged between antibody persistence and clinical severity, similar to the subjects with preserved immune function.
Keywords: COVID-19; SARS-CoV-2 S1/S2; antibody persistence; humoral immune response; immunodepressed patients; neutralizing antibodies; renal transplant recipients.
. 2021 Oct 6;10(10):1289.
doi: 10.3390/pathogens10101289.
Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19
Maria Cappuccilli[SUP] 1 [/SUP], Paolo Ferdinando Bruno[SUP] 2 [/SUP], Alessandra Spazzoli[SUP] 2 [/SUP], Matteo Righini[SUP] 3 [/SUP], Marta Flachi[SUP] 4 [/SUP], Simona Semprini[SUP] 5 [/SUP], Laura Grumiro[SUP] 5 [/SUP], Maria Michela Marino[SUP] 5 [/SUP], Pasqua Schiavone[SUP] 5 [/SUP], Elisabetta Fabbri[SUP] 6 [/SUP], Michela Fantini[SUP] 6 [/SUP], Andrea Buscaroli[SUP] 3 [/SUP], Angelo Rigotti[SUP] 4 [/SUP], Gaetano La Manna[SUP] 1 [/SUP], Vittorio Sambri[SUP] 5 [/SUP], Giovanni Mosconi[SUP] 2 [/SUP]
Affiliations
- PMID: 34684237
- PMCID: PMC8541005
- DOI: 10.3390/pathogens10101289
Abstract
Nephropathic subjects with impaired immune responses show dramatically high infection rates of coronavirus disease 2019 (COVID-19). This work evaluated the ability to acquire and maintain protective antibodies over time in 26 hemodialysis patients and 21 kidney transplant recipients. The subjects were followed-up through quantitative determination of circulating SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month period after clinical and laboratory recovery. A group of 143 healthcare workers with no underlying chronic pathologies or renal diseases recovered from COVID was also evaluated. In both dialysis and transplanted patients, antibody titers reached a zenith around the 3rd month, and then a decline occurred on average between the 270th and 300th day. Immunocompromised patients who lost antibodies around the 6th month were more common than non-renal subjects, although the difference was not significant (38.5% vs. 26.6%). Considering the decay of antibody levels below the positivity threshold (15 AU/mL) as "failure", a progressive loss of immunisation was found in the overall population starting 6 months after recovery. A longer overall antibody persistence was observed in severe forms of COVID-19 (p = 0.0183), but within each group, given the small number of patients, the difference was not significant (dialysis: p = 0.0702; transplant: p = 0.1899). These data suggest that immunocompromised renal patients recovered from COVID-19 have weakened and heterogeneous humoral responses that tend to decay over time. Despite interindividual variability, an association emerged between antibody persistence and clinical severity, similar to the subjects with preserved immune function.
Keywords: COVID-19; SARS-CoV-2 S1/S2; antibody persistence; humoral immune response; immunodepressed patients; neutralizing antibodies; renal transplant recipients.